Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Raman spectrum
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Ready to Use Supplementary Food
United Therapeutics Europe Ltd
Moderate Acute Malnutrition
1 trial -
Recombinant COVID-19 Vaccine (Sf9 Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
Redefine
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Obesity & Overweight
1 trial -
Reduced Nicotine Content Cigarettes
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Dependence
2 trials -
Reduction CTVp1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Regen Matrix-PRP-XLHA
Regeneron Ireland Designated Activity Company (DAC)
Knee Osteoarthritis
1 trial -
Regional lymph node radiotherapy (RNI) including the axilla
The First People's Hospital of Lianyungang
Axillary Lymph Node Dissection
1 trial -
Ringer's solution acetate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholecystolithiasis and Thyroid Nodule
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenic Purpura
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial -
Ropivacaine
Lei Xiaoming
Cystic Adenomatoid Malformation of Lung, Congenital
1 trial -
Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
Routine Medication
The First People's Hospital of Lianyungang
Generalized Anxiety Disorder
1 trial -
Rozerem
Takeda
REM Behavior Disorder
1 trial -
S-ketamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anesthesia
1 trial -
SA58 Nasal Spray
Sinovac Research and Development Co.,
COVID-19
2 trials -
SCOUT-Assisted Review Workflow
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease (CHD)
1 trial -
SGLT2 inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Kidney Transplantation
1 trial -
SPECT/CT imaging with 99mTc-P137 nuclide probe
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
SSRI
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources